2. Search Result
Search Result
Results for "

Benign

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

3

Peptides

6

Natural
Products

7

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Y1097
    Monomethyl phthalate

    2-(Methoxycarbonyl)benzoic acid

    		 Endogenous Metabolite Cancer
    Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule .
    Monomethyl phthalate
  • HY-B0371F
    Terazosin hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride
  • HY-Y1097S
    Monomethyl phthalate-d4

    2-(Methoxycarbonyl)benzoic acid-d4

    		 Isotope-Labeled Compounds Cancer
    Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule .
    Monomethyl phthalate-d4
  • HY-101826A
    ER21355 hydrochloride

    		Phosphodiesterase (PDE) Cancer
    ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .
    ER21355 hydrochloride
  • HY-P3501
    Fexapotide

    NX-1207 free acid

    		 Apoptosis Cancer
    Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide
  • HY-P3501A
    Fexapotide TFA

    NX-1207 TFA

    		 Apoptosis Cancer
    Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide TFA
  • HY-13558
    Atamestane

    SH 489

    		 Estrogen Receptor/ERR Endocrinology
    Atamestane (SH 489) is a specific aromatase inhibitor, which selectively blocks the estrogen biosynthesis resulting from the aromatization of androstenedione and testosterone. Atamestane is a competitive and irreversible inhibitor of estrogen biosynthesis. Atamestane can be used for the research of benign prostatic hyperplasia (BPH) .
    Atamestane
  • HY-Y1097R
    Monomethyl phthalate (Standard)

    		Endogenous Metabolite Cancer
    Monomethyl phthalate (Standard) is the analytical standard of Monomethyl phthalate. This product is intended for research and analytical applications. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule .
    Monomethyl phthalate (Standard)
  • HY-B0371
    Terazosin

    		Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin
  • HY-116379
    RS-100329

    		Adrenergic Receptor Metabolic Disease
    RS-100329 is an α1-adrenergic receptor (α1-AR) antagonist that effectively inhibits α1-adrenergic receptor-mediated contractions of lower urinary tract tissues in vitro and in vivo. RS-100329 can be used in the research of symptoms related to benign prostatic hyperplasia .
    RS-100329
  • HY-B0371A
    Terazosin hydrochloride dihydrate
    Maximum Cited Publications
    6 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride dihydrate
  • HY-N8850
    Angelol G

    		Others Cancer
    Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC50 value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .
    Angelol G
  • HY-B0371FR
    Terazosin hydrochloride (Standard)

    		Adrenergic Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride (Standard)
  • HY-13635A
    Finasteride acetate

    MK-906 acetate

    		 5 alpha Reductase Cancer
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride acetate
  • HY-13635
    Finasteride
    4 Publications Verification

    MK-906

    		 5 alpha Reductase Cancer
    Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride
  • HY-B0371AR
    Terazosin hydrochloride dihydrate (Standard)

    		Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride dihydrate (Standard)
  • HY-103204
    RS100329 hydrochloride

    		Adrenergic Receptor Endocrinology
    RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pKi values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .
    RS100329 hydrochloride
  • HY-115450
    ONO-0300302

    		LPL Receptor Endocrinology Cancer
    ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with Kd of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .
    ONO-0300302
  • HY-U00091
    Gestonorone Capronate

    Gestonorone caproate

    		 Progesterone Receptor Cancer
    Gestonorone Capronate is a progestin for the treatment of benign prostatic hypertrophy and endometrial cancer.
    Gestonorone Capronate
  • HY-165123
    Mepartricin

    		Fungal Parasite Infection
    Mepartricin is a polyene macrolide with antifungal and antiprotozoal activities, widely used in research related to benign prostatic hyperplasia .
    Mepartricin
  • HY-133668
    Monoethyl phthalate

    		Drug Metabolite Cancer
    Monoethyl phthalate is a metabolite of diethyl phthalate. Monoethyl phthalate acts as a urinary biomarker of phthalates exposure indicating the risks of thyroid cancer and benign nodule .
    Monoethyl phthalate
  • HY-W011258
    H-Tyr-Phe-OH

    L-Tyrosyl-L-phenylalanine

    		 Xanthine Oxidase Angiotensin-converting Enzyme (ACE) Inflammation/Immunology Cancer
    H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .
    H-Tyr-Phe-OH
  • HY-B0192AS1
    Alfuzosin-d7 hydrochloride

    SL 77499-10-d7

    		 Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    Alfuzosin-d7 (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
    Alfuzosin-d7 hydrochloride
  • HY-B0192AS
    Alfuzosin-d3 hydrochloride

    SL 77499-10-d3

    		 Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
    Alfuzosin-d3 hydrochloride
  • HY-123710
    GYKI-16084

    		Others Others
    GYKI-16084 is a new compound that can be isolated from dog and rat urine. GYKI-16084 can be used in the research of benign prostatic hyperplasia .
    GYKI-16084
  • HY-P1442
    AdTx1

    		Adrenergic Receptor Cancer
    AdTx1 is a selective α1A-adrenoceptor antagonist (Ki: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .
    AdTx1
  • HY-19144
    ONO-3805

    		Others Others
    ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.
    ONO-3805
  • HY-124375
    IND81

    		Others Infection
    IND81 is an orally active antiprion with IC50 value of 1.95 μM. IND81 reduces abnormal, misfolded, disease-causing forms of benign prion proteins that are normally present on or within cells .
    IND81
  • HY-117856
    IND24

    		Others Infection
    IND24 is a potent antiprion agent with an EC50 value of 1.27 µM. IND24 decreases abnormal, misfolded, pathogenic forms of benign normally occurring prion protein on the cell surface or inside the cell .
    IND24
  • HY-16508
    Ulipristal acetate
    3 Publications Verification

    CDB-2914

    		 Progesterone Receptor Autophagy Endocrinology Cancer
    Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .
    Ulipristal acetate
  • HY-B0192A
    Alfuzosin hydrochloride
    1 Publications Verification

    SL 77499-10

    		 Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride
  • HY-B0192
    Alfuzosin
    1 Publications Verification

    SL 77499

    		 Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin
  • HY-123323
    MK-0434

    		5 alpha Reductase Endocrinology
    MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia .
    MK-0434
  • HY-19702
    PKR activator 3

    		Pyruvate Kinase Metabolic Disease Inflammation/Immunology Cancer
    PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia .
    PKR activator 3
  • HY-161029
    T14-A24

    		Cholinesterase (ChE) Neurological Disease
    T14-A24 is an orally active, reversible, competitive, and selective AChE inhibitor (Ki=22 nM, IC50=6 nM). T14-A24 has benign BBB penetration, remarkable neuroprotective effect, and safe toxicological profile .
    T14-A24
  • HY-16508S
    Ulipristal acetate-d6

    CDB-2914-d6

    		 Isotope-Labeled Compounds Progesterone Receptor Autophagy Endocrinology Cancer
    Ulipristal acetate-d6 is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma[1][2].
    Ulipristal acetate-d6
  • HY-16508R
    Ulipristal acetate (Standard)

    		Progesterone Receptor Autophagy Endocrinology Cancer
    Ulipristal acetate (Standard) is the analytical standard of Ulipristal acetate. This product is intended for research and analytical applications. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .
    Ulipristal acetate (Standard)
  • HY-B0371S
    Terazosin-d8

    		Isotope-Labeled Compounds Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin-d8 is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
    Terazosin-d8
  • HY-B0661C
    Tamsolusin hydrochloride

    YM12617 hydrochloride; LY253351 hydrochloride

    		 Others Endocrinology
    Tamsolusin (YM12617) hydrochloride is a highly selective alpha-1A adrenergic receptor antagonist used in the treatment of benign prostatic hypertrophy, demonstrating effective biological activity in alleviating associated symptoms. Tamsolusin hydrochloride can also be quantified using a validated spectrofluorimetric method, showcasing its potential for routine quality control analysis in pharmaceutical formulations.
    Tamsolusin hydrochloride
  • HY-B0192S
    Alfuzosin-d7

    SL 77499-d7

    		 Adrenergic Receptor Endocrinology
    Alfuzosin-d7 is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].
    Alfuzosin-d7
  • HY-B0192AR
    Alfuzosin hydrochloride (Standard)

    		Adrenergic Receptor Endocrinology
    Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride (Standard)
  • HY-147405
    Tinlorafenib

    PF-07284890; ARRY-461

    		 Raf Cancer
    Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC50s of 4.25 and 2.7 nM for BRAF V600E/V600K respectively. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies .
    Tinlorafenib
  • HY-13635S
    Finasteride-d9

    MK-906-d9

    		 Isotope-Labeled Compounds 5 alpha Reductase Cancer
    Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].
    Finasteride-d9
  • HY-13635R
    Finasteride (Standard)

    MK-906 (Standard)

    		 5 alpha Reductase Cancer
    Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride (Standard)
  • HY-19279A
    JTH-601 free base

    		Others Endocrinology
    JTH-601 Free base is a novel alpha1-adrenoceptor antagonist that exhibits potent activity in inhibiting phenylephrine-induced contractions in lower urinary tract tissues. JTH-601 Free base competitively antagonizes alpha1-adrenoceptor-mediated contractile responses, demonstrating greater potency than prazosin or tamsulosin. JTH-601 Free base is anticipated to be effective in treating urinary outlet obstruction associated with benign prostatic hyperplasia.
    JTH-601 free base
  • HY-103202A
    SNAP5089 Free base

    		Others Cardiovascular Disease
    SNAP5089 Free base is a selective α1A-adrenoceptor antagonist with over 1700-fold selectivity for the α1A subtype, which may have implications for the treatment of hypertension and benign prostatic hypertrophy. SNAP5089 demonstrates significant receptor affinity compared to other clinical drugs, emphasizing its potential therapeutic advantages. SNAP5089's high affinity aligns with its suitability for conditions where precise α1A modulation is desirable.
    SNAP5089 Free base
  • HY-135473
    Chlormadinone

    		Others Others
    Chlormadinone is an antiandrogen drug. Chlormadinone combined with Tamsulosin shows greater improvement in subjective symptoms of BPH .
    Chlormadinone
  • HY-135473R
    Chlormadinone (Standard)

    		Others Others
    Chlormadinone (Standard) is the analytical standard of Chlormadinone. This product is intended for research and analytical applications. Chlormadinone is an antiandrogen drug. Chlormadinone combined with Tamsulosin shows greater improvement in subjective symptoms of BPH .
    Chlormadinone (Standard)
  • HY-162071
    PKM2-IN-5

    		Pyruvate Kinase Cancer
    PKM2-IN-5 (Compound G1) is an inhibitor for pyruvate kinase M2 (PKM2), with IC50 >70 μM .
    PKM2-IN-5
  • HY-10122R
    Silodosin (Standard)

    		Adrenergic Receptor Bacterial Endocrinology Cancer
    Silodosin (Standard) is the analytical standard of Silodosin. This product is intended for research and analytical applications. Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .
    Silodosin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: